These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19447496)

  • 1. Specific recognition of the C-terminal end of A beta 42 by a high affinity monoclonal antibody.
    Axelsen TV; Holm A; Birkelund S; Christiansen G; Ploug M; Holm IE
    Mol Immunol; 2009 Jul; 46(11-12):2267-73. PubMed ID: 19447496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human monoclonal antibodies against amyloid-beta from healthy adults.
    Geylis V; Kourilov V; Meiner Z; Nennesmo I; Bogdanovic N; Steinitz M
    Neurobiol Aging; 2005 May; 26(5):597-606. PubMed ID: 15708434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel monoclonal antibody specific for the amino-truncated beta-amyloid Abeta5-40/42 produced from caspase-cleaved amyloid precursor protein.
    Murayama KS; Kametani F; Tabira T; Araki W
    J Neurosci Methods; 2007 Apr; 161(2):244-9. PubMed ID: 17207535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
    Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
    Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders.
    Murphy GM; Forno LS; Higgins L; Scardina JM; Eng LF; Cordell B
    Am J Pathol; 1994 May; 144(5):1082-8. PubMed ID: 8178931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation.
    Lafaye P; Achour I; England P; Duyckaerts C; Rougeon F
    Mol Immunol; 2009 Feb; 46(4):695-704. PubMed ID: 18930548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific reactivity of mild/severe Alzheimer's disease patient's sera to antibody against Abeta1-40 epitope 17-21.
    Bolukbasi Hatip FF; Matsunaga Y; Yamada T
    Acta Neurol Scand; 2008 Jun; 117(6):404-8. PubMed ID: 18005218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.
    Miles LA; Wun KS; Crespi GA; Fodero-Tavoletti MT; Galatis D; Bagley CJ; Beyreuther K; Masters CL; Cappai R; McKinstry WJ; Barnham KJ; Parker MW
    J Mol Biol; 2008 Mar; 377(1):181-92. PubMed ID: 18237744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease--a spirochetosis?
    Miklossy J
    Neuroreport; 1993 Jul; 4(7):841-8. PubMed ID: 8369471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody binding to a peptide but not the whole protein by recognition of the C-terminal carboxy group.
    Liang TC; Luo W; Hsieh JT; Lin SH
    Arch Biochem Biophys; 1996 May; 329(2):208-14. PubMed ID: 8638953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide.
    König G; Graham P; Bushnell A; Webster S; Wunderlich D; Perlmutter LS
    Ann N Y Acad Sci; 1996 Jan; 777():344-55. PubMed ID: 8624111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates.
    van Helmond Z; Heesom K; Love S
    J Neurosci Methods; 2009 Jan; 176(2):206-12. PubMed ID: 18824027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease.
    Bednar MM
    IDrugs; 2009 Sep; 12(9):566-75. PubMed ID: 19697276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune responses to peptides derived from the beta-amyloid peptide C-terminal sequence.
    Miller DL; Potempska A; Mehta PD
    Amyloid; 2007 Mar; 14(1):39-50. PubMed ID: 17453624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding and uptake of A beta1-42 by primary human astrocytes in vitro.
    Nielsen HM; Veerhuis R; Holmqvist B; Janciauskiene S
    Glia; 2009 Jul; 57(9):978-88. PubMed ID: 19062178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
    Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterisation of the novel amyloid-beta peptide-induced protein p17.
    Nehar S; Mishra M; Heese K
    FEBS Lett; 2009 Oct; 583(19):3247-53. PubMed ID: 19755123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.